Indinavir resistance evolution in one human immunodeficiency virus type 1 infected patient revealed by single-genome amplification
- PMID: 20960178
- PMCID: PMC8227899
- DOI: 10.1007/s12250-010-3122-4
Indinavir resistance evolution in one human immunodeficiency virus type 1 infected patient revealed by single-genome amplification
Abstract
Human Immunodeficiency Virus Type 1 exists in vivo as quasispecies, and one of the genome's characteristics is its diversity. During the antiretroviral therapy, drug resistance is the main obstacle to effective viral prevention. Understanding the molecular evolution process is fundamental to analyze the mechanism of drug resistance and develop a strategy to minimize resistance.
Objective: The molecular evolution of drug resistance of one patient who had received reverse transcriptase inhibitors for a long time and had treatment which replaced Nevirapine with Indinavir was analyzed, with the aim of observing the drug resistance evolution pathway.
Methods: The patient, XLF, was followed-up for six successive times. The viral populations were amplified and sequenced by single-genome amplification. All the sequences were submitted to the Stanford HIV Drug Resistance Database for the analysis of genotypic drug resistance.
Results: 149 entire protease and 171 entire reverse transcriptase sequences were obtained from these samples, and all sequences were identified as subtype B. Before the patient received Indinavir, the viral population only had some polymorphisms in the protease sequences. After the patient began Indinavir treatment, the variants carrying polymorphisms declined while variants carrying the secondary mutation G73S gained the advantage. As therapy was prolonged, G73S was combined with M46I/L90M to form a resistance pattern M46I/G73S/L90M, which then became the dominant population. 97.9% of variants had the M46I/G73S/L90M pattern at XLF6. During the emergence of protease inhibitors resistance, reverse transcriptase inhibitors resistance maintained high levels.
Conclusion: Indinavir-resistance evolution was observed by single-genome amplification. During the course of changing the regimen to incorporate Indinavir, the G73S mutation occurred and was combined with M46I/L90M.
Comment in
-
Indinavir resistance evolution: a comment.Virol Sin. 2011 Feb;26(1):72. doi: 10.1007/s12250-011-3173-6. Epub 2011 Feb 18. Virol Sin. 2011. PMID: 21331894 Free PMC article. No abstract available.
Similar articles
-
Indinavir resistance evolution: a comment.Virol Sin. 2011 Feb;26(1):72. doi: 10.1007/s12250-011-3173-6. Epub 2011 Feb 18. Virol Sin. 2011. PMID: 21331894 Free PMC article. No abstract available.
-
Drug resistance in patients experiencing early virological failure under a triple combination including indinavir.AIDS. 2001 Sep 7;15(13):1701-6. doi: 10.1097/00002030-200109070-00014. AIDS. 2001. PMID: 11546946
-
HIV type 1 pol gene diversity and antiretroviral drug resistance mutations in Santos, Brazil.AIDS Res Hum Retroviruses. 2008 Mar;24(3):347-53. doi: 10.1089/aid.2007.0203. AIDS Res Hum Retroviruses. 2008. PMID: 18327988
-
Polymorphism in HIV-1 non-subtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution.AIDS Rev. 2003 Jan-Mar;5(1):25-35. AIDS Rev. 2003. PMID: 12875105 Review.
-
Insertions in the human immunodeficiency virus type 1 protease and reverse transcriptase genes: clinical impact and molecular mechanisms.Antimicrob Agents Chemother. 2005 Jul;49(7):2575-82. doi: 10.1128/AAC.49.7.2575-2582.2005. Antimicrob Agents Chemother. 2005. PMID: 15980322 Free PMC article. Review. No abstract available.
Cited by
-
Characterization of EIAV env Quasispecies during Long-Term Passage In Vitro: Gradual Loss of Pathogenicity.Viruses. 2019 Apr 24;11(4):380. doi: 10.3390/v11040380. Viruses. 2019. PMID: 31022927 Free PMC article.
-
Indinavir resistance evolution: a comment.Virol Sin. 2011 Feb;26(1):72. doi: 10.1007/s12250-011-3173-6. Epub 2011 Feb 18. Virol Sin. 2011. PMID: 21331894 Free PMC article. No abstract available.
-
Impact of Y181C and/or H221Y mutation patterns of HIV-1 reverse transcriptase on phenotypic resistance to available non-nucleoside and nucleoside inhibitors in China.BMC Infect Dis. 2014 May 5;14:237. doi: 10.1186/1471-2334-14-237. BMC Infect Dis. 2014. PMID: 24885612 Free PMC article.
-
Single genome amplification of proviral HIV-1 DNA from dried blood spot specimens collected during early infant screening programs in Lusaka, Zambia.J Virol Methods. 2014 Jul;203:97-101. doi: 10.1016/j.jviromet.2014.03.001. Epub 2014 Mar 22. J Virol Methods. 2014. PMID: 24667303 Free PMC article.
References
-
- Bélec L., Piketty C., Si-Mohamed A., et al. High levels of drug-resistant Human Immunodeficiency Virus variants in patients exhibiting increasing CD4+ T cell counts despite virologic failure of protease inhibitor-containing antiretroviral combination therapy. J Infect Dis. 2000;181(5):1808–1812. doi: 10.1086/315429. - DOI - PubMed
-
- Clavel F., Hance A. J. HIV drug resistance. N Engl J Med. 2004;350(10):1023–1035. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials